



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

IntReALL SR 2010

Acute lymphoblastic leukaemia (ALL), is the most common type of blood cancer in children and adolescents. Without therapy, ALL leads to severe diseases and organ disorders with a fatal outcome. With the current standard treatment, the majority of ALL patients can already be cured. In 15-20% of ALL patients, however, the leukaemia returns despite initial treatment, which worsens the prognosis and makes further therapy necessary. The Charité - Universitätsmedizin Berlin in Germany is responsible for the international implementation of the study (sponsor). In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the conduct of the study (sponsor representative).

The main objective of the study is to establish a common treatment protocol for future patients at the European level and beyond, which will provide the best possible current cure for ALL relapse. This study therefore compares two proven treatment protocols for ALL relapses at standard risk, although it is not known whether one of the two is more effective than the other. Both are based on very similar drugs, but differ in the composition of the individual therapeutic elements. Until February 2019 the study has also investigated whether the new drug Epratuzumab could improve the prognosis in addition to conventional therapy.

Contact details for the sponsor representative in Switzerland:

Partner Relations
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89